“Pharmaceuticals are massively larger markets than what people are focused on right now.”
LinkedIn cofounder Reid Hoffman believes the biggest future opportunity in artificial intelligence is not in chatbots or enterprise software, but in drug discovery. Speaking on The Possible Podcast, Hoffman argued that the real value of AI will show up in healthcare, where drug development is slow, expensive, and highly profitable once breakthroughs happen.
He pointed to the pharmaceutical industry as a space where AI can compress timelines that usually take more than a decade into much shorter research cycles. Hoffman also stressed that AI drug discovery is not a “winner-takes-all” market. He compared it to the GLP-1 drug category, where multiple companies can succeed at the same time and still generate billions in revenue.
For him, the current excitement around chatbot companies like OpenAI and Anthropic is only one phase of the AI cycle. The next phase, he says, will be far more connected to biology and medicine.
Hoffman is not just commenting from the sidelines. He co-founded “manas.ai”, a biotech company focused on using AI systems to speed up how new drugs are discovered and tested. That move reflects a growing shift across Silicon Valley, where AI is moving from digital tasks into physical science problems like chemistry, biology, and medicine.
Drug discovery has long been one of the most expensive areas in science. It often takes billions of dollars and years of failed trials before a successful medicine reaches the market. AI tools are now being trained to scan biological data, predict molecular behavior, and suggest promising drug candidates faster than traditional lab methods.
Hoffman’s argument is simple: the biggest financial upside in AI will come from industries where a single breakthrough can reshape entire markets. Healthcare fits that pattern more than most sectors. The report highlights that AI-driven biotech startups have surged since the COVID-19 pandemic, as investors look for ways to reduce the cost and time of medical research.
Hoffman’s view also challenges a common assumption in the tech industry that AI progress will be dominated mainly by chatbots and general-purpose assistants. Instead, he sees a shift toward specialized systems built for science, medicine, and industrial research. He believes these areas carry much larger “total addressable markets” than consumer AI tools.
In simple terms, the money potential in medicine is far bigger than the current AI apps most people interact with daily. The idea is already attracting strong attention from investors and research labs. Companies are now racing to build systems that can design molecules, simulate drug reactions, and reduce failed experiments before they reach clinical stages.
This approach could significantly cut the cost of developing new treatments for diseases that currently have limited or slow-moving research pipelines. Hoffman’s broader message is that AI’s biggest economic impact may not be visible in everyday apps. Instead, it may happen behind the scenes in laboratories, hospitals, and biotech companies.
That shift would place artificial intelligence at the center of how new medicines are created, tested, and approved. It also means the next wave of AI competition may look very different from the current race between chatbot companies. Rather than competing for user attention, future AI leaders may compete on scientific breakthroughs and medical impact.
For Hoffman, that is where the real “gold rush” begins. Not in conversations with machines, but in the discovery of new medicines that can change human health outcomes at scale. And in that race, biology may become the most important frontier of artificial intelligence. You can leave your thoughts at the comment box. What do you think it’s the next AI gold rush?
